Cite this answer
Sermorelin: quick citable summary
Sermorelin is listed by PeptaHub as a muscle & growth peptide with a legal compounding legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Sermorelin: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/sermorelin. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/sermorelin.
What is Sermorelin?
Sermorelin is the shortest active GHRH fragment (amino acids 1-29), formerly FDA-approved as Geref. It stimulates pulsatile GH release while preserving the natural feedback loop, making it one of the most studied anti-aging peptides.
Overview
Sermorelin is the shortest fully functional fragment of growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids. It was FDA-approved in 1997 as Geref for diagnosing and treating growth hormone deficiency in children, though it was discontinued commercially in 2008. It remains one of the most well-studied GH-releasing peptides with established clinical safety data.
Mechanism of action
Sermorelin binds to the GHRH receptor on anterior pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone. Unlike exogenous GH administration, sermorelin preserves the hypothalamic-pituitary feedback loop, maintaining physiological GH regulation. It stimulates all five somatotroph cell subtypes.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| anti-aging / GH optimization | subcutaneous | 200–500 mcg | daily at bedtime | Inject before sleep to synergize with natural nocturnal GH pulse. 3-6 month cycles recommended. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Sermorelin research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? The Sermorelin dose calculator is preloaded with these ranges, or use the general dose unit converter.
Research summary
The pivotal pediatric data come from Thorner et al. (JCEM 1996), a multicenter open-label study in 110 previously untreated prepubertal GH-deficient children, where mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months. In older adults, Khorram et al. (JCEM 1997) ran a 5-month single-blind placebo-controlled trial of the GHRH(1-29) analog in 19 men and women aged 55-71: nocturnal GH and IGF-1 rose significantly in both sexes, skin thickness increased in both, and lean body mass, insulin sensitivity and libido improved in men only. That study specifically reported that sleep quality was unaffected, so the common claim that sermorelin improves slow-wave sleep is not supported by it. Trials of the related stabilized GHRH analog tesamorelin (Baker et al., Arch Neurol 2012) showed favorable cognitive effects in older adults, but those results are for tesamorelin rather than sermorelin.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Sermorelin for synergistic effects.
Legal status
Sermorelin is the exception among the growth hormone secretagogues on this site: it can be legally compounded. It was FDA-approved as Geref in 1997 and withdrawn from the US market in 2008 for business rather than safety reasons, which leaves it eligible for use in 503A compounding as a component of a previously approved drug. It was never placed on the Category 2 list, it was not part of the FDA's April 15, 2026 action on 12 peptides, and it is not under Pharmacy Compounding Advisory Committee review. Compounded sermorelin still requires a prescription from a licensed prescriber and a licensed compounding pharmacy; the compounded product itself is not an FDA-approved drug and has not been reviewed by the FDA for safety or efficacy. Verify current federal and state rules before relying on access claims.
Sourcing & access
Research compound
Sermorelin is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Sermorelin is a growth hormone-releasing hormone (GHRH) analogue used to stimulate the pituitary gland to produce natural growth hormone. It received FDA approval in 1997 under the brand name Geref for pediatric growth hormone deficiency. Off-label uses include adult anti-aging, body composition improvement, sleep quality enhancement, and general GH optimization through compounding pharmacies.
Sermorelin stimulates the pituitary to release GH in a pulsatile, physiologically regulated pattern, preserving the hypothalamic-pituitary feedback loop that governs the GH axis. This prevents supraphysiological GH or IGF-1 levels. Exogenous synthetic HGH bypasses this feedback entirely, suppresses natural GH secretion over time, and carries higher risks of side effects including insulin resistance and carpal tunnel syndrome.
Sermorelin was FDA-approved in 1997 but its branded pharmaceutical form (Geref) was voluntarily discontinued in 2008 for business rather than safety reasons. Because it is a component of a previously approved drug, it remains eligible for 503A compounding, and compounding pharmacies can prepare it for patients with a valid prescription. It was not part of the FDA's April 15, 2026 action on 12 peptides and is not under Pharmacy Compounding Advisory Committee review. The compounded product itself is not FDA-approved.
The most common research and off-label protocol uses 200 to 500 micrograms administered subcutaneously at bedtime, which aligns with the natural nocturnal GH pulse. Cycles typically run 3 to 6 months before reassessment. Bedtime dosing is preferred because it amplifies the largest physiological GH pulse that naturally occurs during slow-wave sleep.
The most commonly reported side effects are injection site reactions including redness, pain, and swelling. Systemic effects may include facial flushing, headache, dizziness, and transient sleepiness, typically occurring shortly after injection. These effects are generally mild and dose-dependent. Serious adverse events are uncommon but may include fluid retention or hypersensitivity reactions in rare cases.
Research references
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and womenPubMed
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?PubMed
- Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study GroupPubMed
- Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy agingPubMed
- Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trialPubMed
Discussion (0)
replies to this reviewNo replies yet. Be the first to ask a question or add context.